Accessibility Links

  1. Skip to Main Navigation
  2. Skip to Main Content



Rituxan Fc-Gamma Receptor Binding Assays

BioOutsource provides a comprehensive portfolio of off-the-shelf Fc-Gamma Receptor (FcR) binding assays for Rituxan by Surface Plasmon Resonance using the Biacore T-200. These Rituxan Fc Receptor binding assays can be used to rapidly accelerate development and manufacture of biosimilar Rituxan in a cost effective manner. Our assays are used to support Rituxan biosimilar process development, assessing material produced from different clones, different production processes or prepared in different formulations. We offer industry leading Rituxan comparability and Rituxan characterisation services and can be adapted to function as qualified or validated GMP lot release and stability studies for your product.

The Fc-Gamma Receptors (FcR) are members of the immunoglobulin superfamily and play a critical role in the function of Rituxan (Rituximab). The Fc-Gamma Receptors (FcR) can be divided into three types, Fc-Gamma Receptor I (FcGRI), CD64, Fc-Gamma Receptor II (FcGRII), CD32 and Fc-Gamma Receptor III (FcGRIII), CD16. Both the FcRII and FcRIII can be further divided into FcRIIa/FcRIIb and FcRIIIa/FcRIIIb. Historically, these receptors have been categorised based upon their affinity for specific IgG subclasses and whether their binding initiates activating or inhibitory signals. Following binding of Rituxan (rituximab) to CD20, the subsequent binding of the FcRs is crucial step for the initiation and control of cell-mediated effector functions of the immune system. Whilst FcRI is capable of binding monomeric IgG with high affinity and both FcRII and FcRIII have the capacity to bind IgG complexes and the binding can be affected by genetic polymorphism of the receptors as well as different glycosylation patterns in the Fc region of the Rituxan.

The Rituxan Fc-Gamma Receptor assays offered by BioOutsource are performed using the Biacore T200, which is a versatile, label-free system with exceptional sensitivity and as the most recent SPR machine from GE Healthcare, it’s increased sensitivity provides the optimal platform for evaluation of Rituxan Fc Receptor interactions. The following Rituxan (rituximab) Fc-Gamma Receptor assays are offered by BioOutsource:

  • Rituxan Fc-Gamma Receptor I (FcRI) binding assay by SPR
  • Rituxan Fc-Gamma Receptor IIa (FcRIIa) binding assay by SPR
  • Rituxan Fc-Gamma Receptor IIb (FcRIIb) binding assay by SPR
  • Rituxan Fc-Gamma Receptor IIIa (v/v) (FcRIIIa v/v) binding assay by SPR
  • Rituxan Fc-Gamma Receptor IIIa (f/f) (FcRIIIa f/f) binding assay by SPR
  • Rituxan Fc-Gamma Receptor IIIb (FcRIIIb) binding assay by SPR